In 2016, Centonze et al. (40) demonstrated that the endogenous concentration of CCL5 in the cerebrospinal fluid of MS patients suffering from the active form of the disease was largely increased when compared to healthy individuals and to patients at the inactive stage of disease. Here, CCL5 is linked to myeloid sarcoma.